{"id":5098,"date":"2026-05-13T17:30:00","date_gmt":"2026-05-13T15:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5f7a476d8f96d6c49c11802fe0690676"},"modified":"2026-05-13T17:30:00","modified_gmt":"2026-05-13T15:30:00","slug":"epineuron-receives-fda-510k-clearance-for-evala-nerve-stimulator","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=5098","title":{"rendered":"Epineuron Receives FDA 510(k) Clearance for Evala\u00ae Nerve Stimulator"},"content":{"rendered":"

\nEvolution in intraoperative nerve identification and evaluation.<\/i><\/p><\/a><\/a>

MISSISSAUGA, Ontario--(BUSINESS WIRE)--#BioelectronicMedicine<\/a>--Epineuron, a medical device company pioneering bioelectronic medicine, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Evala\u00ae Nerve Stimulator<\/b>. This handheld, intraoperative electrical stimulation device is engineered to provide surgeons with a rapid and accurate solution for nerve identification and functional evaluation of different nerve sizes, large and small. This milestone marks a significant expansion of the company\u2019s portfolio and commercial footprint of its proprietary bioelectronic platform for peripheral nerve care.<\/p>

\nDr. Jana Dengler, MD, MASc, MHSc, a peripheral nerve surgeon at the renowned Sunnybrook Health Sciences Centre in Toronto, ON, was among the early users of Evala\u00ae. \u201cI am impressed with the versatility of the product allowing me to evaluate nerves in scarred revision surgeries, nerve transfers, under extended tourniquet time, and in conjunction with PeriPulse,\u201d said Dr. Dengler.<\/p>

\n\"At Epineuron, we\u2019ve listened closely to surgeons that expressed a significant need for more than just nerve stimulation hardware, they needed a cohesive ecosystem for nerve care,\" said Sergio Aguirre, CEO. \"We\u2019ve broadened our technology by complementing PeriPulse\u00ae<\/b> with Evala\u00ae<\/b> to support surgeons during the most demanding aspects of a procedure. Whether it\u2019s protecting nerves in real-time or boosting their regenerative capacity afterward, our technology integrates seamlessly into the surgical workflow to enhance efficiency and offer patients the best path to recovery. \"<\/p>

\nThe expansion of Epineuron\u2019s portfolio reflects its dedication to delivering transformative bioelectronic advancements to the field of peripheral nerve care, highlighting the company\u2019s enduring promise to clinicians and the patients they serve.<\/p>

\nFor more information, visit www.epineurontech.com<\/a>.<\/p>

\nAbout Epineuron<\/b><\/p>

\nEpineuron Technologies Inc. is a commercial-stage medical device company dedicated to restoring function through our proprietary bioelectronic solutions for nerve evaluation and regeneration. Headquartered in Mississauga, ON, our mission is to empower clinicians and improve patient quality of life by providing simple, intuitive, and effective bioelectronic solutions that streamline decision-making and unlock the therapeutic potential of the peripheral nervous system.<\/p> Contacts<\/b>

\nDr. Mike Willand, PhD, PEng\ninfo@epineurontech.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Evolution in intraoperative nerve identification and evaluation.MISSISSAUGA, Ontario–(BUSINESS WIRE)–#BioelectronicMedicine–Epineuron, a medical device company pioneering bioelectronic medicine, today announced that it has received U.S. Food and Dr…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5098","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5098"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5098\/revisions"}],"predecessor-version":[{"id":5099,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5098\/revisions\/5099"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}